Targus International LLC v. Victorinox Swiss Army, Inc.

District Court, D. Delaware·Decided June 4, 2021·No. 1:20-cv-00464·Unknown

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE

TARGUS INTERNATIONAL LLC,

Plaintiff; v. Civil Action No. 20-cv-464-RGA

VICTORINOX SWISS ARMY, INC.,

Defendant.

MEMORANDUM ORDER

Before me is Defendant’s motion for leave to amend. (D.I. 80). The matter has been fully briefed. (D.I. 81, 89, 94). For the reasons set forth below, Defendant’s motion is granted. I. BACKGROUND On April 2, 2020, Plaintiff Targus filed a Complaint alleging infringement of U.S. Patent No. 8,567,578 (“the ’578 Patent”) by Defendant Victorinox. (D.I. 1). On June 8, 2020, Victorinox filed an answer in which, among other things, it alleged unenforceability of the ’578 Patent due to inequitable conduct and counterclaimed for declaratory judgment of unenforceability of the ’578 Patent due to inequitable conduct and for an antitrust violation. (D.I. 11). The Scheduling Order states that the deadline to amend pleadings was August 21, 2020. (D.I. 18 at 1). On December 18, 2020, Defendant indicated to Plaintiff that it would seek leave to amend its answer to assert additional inequitable conduct and antitrust claims based on Targus’ CCB1, CDB1, and CFP3 bags. (D.I. 82, Ex. 9 at 3–4). Plaintiff stated it would oppose Defendant’s amendment. (D.I. 82, Ex. 12 at 1). The parties could not resolve their dispute. (D.I. 81 at 12). The instant motion followed. II. LEGAL STANDARD Federal Rule of Civil Procedure 15(a)(2) states that, apart from amendments as a matter of course, “a party may amend its pleading only with the opposing party’s written consent or the court’s leave. The court should freely give leave when justice so requires.” FED. R. CIV. P.

15(a)(2). The Third Circuit has construed Rule 15 generously, instructing that “absent undue or substantial prejudice, an amendment should be allowed under Rule 15(a) unless ‘denial [can] be grounded in bad faith or dilatory motive, truly undue or unexplained delay, repeated failure to cure deficiency by amendments previously allowed or futility of amendment.’” Long v. Wilson, 393 F.3d 390, 400 (3d Cir. 2004) (quoting Lundy v. Adamar of New Jersey, Inc., 34 F.3d 1173, 1196 (3d Cir. 1994)) (emphasis omitted). An amendment is futile if it “would fail to state a claim upon which relief could be granted.” In re Burlington Coat Factory Sec. Litig., 114 F.3d 1410, 1434 (3d Cir. 1997). The futility analysis follows the standard that applies to a motion to dismiss under Rule 12(b)(6). Id. A request submitted after the court’s deadline to amend must also meet the “good cause”

standard of Rule 16(b)(4). Premier Comp Solutions v. UPMC, 970 F.3d 316, 319 (3d Cir. 2020). That rule provides, “A schedule may be modified only for good cause and with the judge’s consent.” FED. R. CIV. P. 16(b)(4). “‘Good cause’ exists when the [s]chedule cannot reasonably be met despite the diligence of the party seeking the extension.” ICU Medical, Inc. v. Ryman Techs., Inc., 674 F. Supp. 2d 574, 577 (D. Del. 2009). Unlike Rule 15(a), the Rule 16(b) standard focuses on the “diligence of the movant, and not on prejudice to the non-moving party.” Roquette Freres v. SPI Pharma, Inc., 2009 WL 1444835, at *4 (D. Del. May 21, 2009). The Third Circuit recently clarified that the analysis under Rule 16(b)(4) logically precedes the Rule 15(a)(2) analysis. Premier Comp, 970 F.3d at 319 (“A party must meet [Rule 16(b)’s] standard before a district court considers whether the party also meets Rule 15(a)’s more liberal standard.”). III. DISCUSSION The ’578 Patent describes and claims checkpoint-friendly computer cases that allow

travelers to pass through airport security without removing laptops from their cases. Defendant Victorinox argues that during the prosecution of the ’578 Patent, Plaintiff Targus failed to inform the patent office that it had begun to manufacture and sell two computer backpacks and a briefcase, the Targus CCB1, Targus CDB1, and Targus CFP3 (“Targus Products”). (D.I. 81 at 4). Victorinox alleges that the three products are all material prior art, anticipate numerous claims of the ’578 Patent, and render multiple claims of the ’578 Patent obvious when viewed in conjunction with additional prior art. (Id.). A. RULE 16(b)(4) DILIGENCE Victorinox asserts that it did not become aware of the Targus Products until “mid to late October,” after the August 21, 2020 deadline for amending pleadings and after the October 9,

2020 deadline for serving initial invalidity contentions, because Targus did not produce the documents related to the products despite Victorinox’s July 2, 2020 requests for production. (D.I. 81 at 6, 9). Victorinox states that after learning about the Targus Products, it independently obtained samples from third-party internet retailers, supplemented its invalidity contentions on November 4, 2020, and then on November 11, 2020, filed discovery requests seeking “to confirm the prior art status of the products and discover whether and when the inventors had knowledge of the products.” (Id. at 9). Victorinox contends that the process of independently obtaining the bags was “time-consuming” and was hindered by the lack of information provided by sellers relating to dates relevant for determining if the products were prior art. (Id.) Victorinox states that on December 11, 2020, Targus’ discovery responses confirmed that the Targus Products were prior art, but that the same responses also argued that Victorinox could not take discovery related to the inventors’ knowledge of the Targus Products since it is “not relevant to any claim or defense in this lawsuit.” (Id.; D.I. 82-8 at 6–9.) Victorinox writes that on December

18, 2020, it sought to meet and confer about the motion before the Court. Targus argues that the Targus Products have been publicly available since 2001 and documentation of their sale has been verifiable online for just as long. Targus writes that because of this, Victorinox could have included the proposed amendments in its initial pleadings or could have amended its pleadings before the deadline. (D.I. 89 at 5). Additionally, Targus contends that Victorinox’s supplemental invalidity contentions served on November 4, 2020 had claim charts containing images and dates for each of the Targus Products and, therefore, Victorinox did not need discovery to confirm the Targus Products were prior art and thus delayed in filing its motion for leave to amend. (Id. at 7). Targus states that Victorinox delayed further because it did not file this motion until January 15, 2020, close to a month after Victorinox indicated it planned

to amend its pleading on December 18, 2020. (Id. at 8). Due to the “heavy burden” in proving a claim of inequitable conduct and the fact that an inequitable conduct claim relies on evidence often only able to be obtained through discovery, it is common for a motion for leave to amend related to a claim of inequitable conduct to come after the deadline for amending pleadings. Lipocine Inc. v. Clarus Therapeutics, Inc., 2020 WL 4794576 at *3 (D. Del. Aug. 18, 2020).

Free access — add to your briefcase to read the full text and ask questions with AI

Targus International LLC v. Victorinox Swiss Army, Inc., (D. Del. 2021).

Targus International LLC v. Victorinox Swiss Army, Inc. (Targus International LLC v. Victorinox Swiss Army, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Exergen Corp. v. Wal-Mart Stores, Inc.
575 F.3d 1312 (Federal Circuit, 2009)
In Re: Rockefeller Center Properties, Inc. Securities Litigation, Charal Investment Company Inc., a New Jersey Corporation C.W. Sommer & Co., a Texas Partnership, on Behalf of Themselves and All Others Similarly Situated Alan Freed Jerry Crance Helen Scozzanich Sheldon P. Langendorf Rita Walfield Robert Flashman Renee B. Fisher Foundation Inc. Frank Debora Wilson White Stanley Lloyd Kaufman, Jr. Joseph Gross v. David Rockefeller Goldman Sachs Mortgage Co. Goldman Sachs Group Lp Goldman Sachs & Co. Whitehall Street Real Estate Limited Partnership v. Wh Advisors Inc. v. Wh Advisors Lp v. Daniel M. Neidich Peter D. Linneman Richard M. Scarlata Frank Debora Wilson White Stanley Lloyd Kaufman, Jr. Joseph Gross, Charal Investment Company Inc., a New Jersey Corporation C.W. Sommer & Co., a Texas Partnership, on Behalf of Themselves and All Others Similarly Situated Alan Freed Jerry Crance Helen Scozzanich Sheldon P. Langendorf Rita Walfield Robert Flashman Renee B. Fisher Foundation Inc. Frank Debora Wilson White Stanley Lloyd Kaufman, Jr. Joseph Gross v. David Rockefeller Goldman Sachs Mortgage Co. Goldman Sachs Group Lp Goldman Sachs & Co. Whitehall Street Real Estate Limited Partnership v. Wh Advisors Inc. v. Wh Advisors Lp v. Daniel M. Neidich Peter D. Linneman Richard M. Scarlata Charal Investment Company Inc. C.W. Sommer & Co. Renee B. Fisher Foundation Helen Scozzanich Jerry Crance Alan Freed Sheldon P. Langendorf Rita Walfield Robert Flashman
311 F.3d 198 (Third Circuit, 2002)
Curtis Long v. Harry Wilson, Superintendent
393 F.3d 390 (Third Circuit, 2004)
Icu Medical, Inc. v. Rymed Technologies, Inc.
674 F. Supp. 2d 574 (D. Delaware, 2009)
Collette Davis v. Abington Mem Hosp
765 F.3d 236 (Third Circuit, 2014)
Lundy v. Adamar of New Jersey, Inc.
34 F.3d 1173 (Third Circuit, 1994)
Regeneron Pharmaceuticals, Inc. v. Merus N.V.
864 F.3d 1343 (Federal Circuit, 2017)
Premier Comp Solutions LLC v. UPMC
970 F.3d 316 (Third Circuit, 2020)
Biogen Ma Inc. v. Emd Serono, Inc.
976 F.3d 1326 (Federal Circuit, 2020)